HighTower Advisors
LEXX icon

HighTower Advisors’s Lexaria Bioscience LEXX Stock Holding History

HighTower Advisors’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,000
Closed -$35.9K – 3882
2025
Q1 		$35.9K Sell
21,000
-23
-0.1% -$39 ﹤0.01% 3480
2024
Q4 		$44.1K Buy
21,023
+8,000
+61% +$19.7K ﹤0.01% 3471
2024
Q3 		$40K Buy
+13,023
New +$41.4K ﹤0.01% 3436

Other funds holding LEXX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HighTower Advisors's LEXX Position: Q2 2025 in Review

HighTower Advisors sold out of Lexaria Bioscience (LEXX) in Q2 2025, closing a stake of 21,000 shares — an estimated $35.9K sold.

HighTower Advisors first reported a position in LEXX in Q3 2024 and held it in 3 quarters. The position peaked at $44.1K in Q4 2024. 21 funds tracked by Wall St. Rank hold LEXX as of Q2 2025.

  • HighTower Advisors reported no remaining Lexaria Bioscience position as of Q2 2025 after selling out during the quarter.
  • HighTower Advisors sold 21,000 Lexaria Bioscience shares in Q2 2025, an estimated $35.9K.
  • HighTower Advisors first reported a position in Lexaria Bioscience in Q3 2024 and held it in 3 quarters.
  • HighTower Advisors's Lexaria Bioscience position peaked at $44.1K in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.